T-cell-receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function

B. Liang, S. Ardestani, J. J. Marchalonis, R. R. Watson

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

C57BL/6 mice were injected with different doses of human T-cell receptor (TCR) Vβ8.1 CDR1 peptide at different times after murine retrovirus (LP-BM5) infection. Injection with TCR Vβ8.1 CDR1 peptide largely prevented the retrovirus-induced reduction in B- and T-cell proliferation, and T-helper 1 (Th1) cytokines [interleukin-2 (IL-2) and interferon-γ (IFN-γ)] secretion. It also suppressed T-helper 2 (Th2) cytokines (IL-6 and IL-10) production, which was stimulated by retrovirus infection. These effects were accomplished using at least 100 μg of peptide per mouse and the most effective dose of peptide had to be given within 4 weeks after retrovirus infection. Immunization with doses above 100 μg/mouse as long as 4 weeks postinfection maintained natural killer (NK) cell activity during retrovirus infection. Reducing the dose of peptide or delaying it until the disease progressed towards early murine acquired immune deficiency syndrome (AIDS) allowed development of immune dysfunction. These studies provide data suggesting that immune dysfunction, induced by murine retrovirus infection, was largely prevented by TCR Vβ CDR1 peptide injection.

Original languageEnglish (US)
Pages (from-to)198-204
Number of pages7
JournalImmunology
Volume87
Issue number2
DOIs
StatePublished - Jan 1 1996

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this